Etanercept changes

From 1 November, authority requirements regarding etanercept for the treatment of children and adolescents with severe chronic plaque psoriasis will change The Pharmaceutical Benefits Advisory Committee’s recommendations led to the changes, which will see PBS listings for initial therapy change from Authority Required (Written) to Authority Required (telephone/immediate online assessment). The PBS listings to complete a